Gilead Q1 earnings: Strong HIV business balances out low Covid and cancer drug sales
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of revenue compared to this time last year. The Foster City ...
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of revenue compared to this time last year.
The Foster City ...
